Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Enobosarm

MARKETED

selective androgen receptor modulator (SARM); muscle-preserving combo with GLP-1RA

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 1

Enobosarm is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Enobosarm MARKETED
Body composition Mixed
Very low evidence

Veru phase-2b QUALITY trial (NCT06282458): enobosarm added to semaglutide in older adults (>=60 y) reported large reductions in lean-mass loss and a physical-function...

Veru Inc., Phase-2b QUALITY topline press release, 27 Jan 2025; NCT06282458 Source
Full findingVeru phase-2b QUALITY trial (NCT06282458): enobosarm added to semaglutide in older adults (>=60 y) reported large reductions in lean-mass loss and a physical-function signal versus placebo+semaglutide. This is muscle PRESERVATION (anti-catabolic). NON-GRADUATING: the figures are a company press topline only, with no peer-reviewed publication.
PopulationQUALITY phase-2b dose-finding RCT, N=168, double-blind placebo-controlled, 16 weeks, adults >=60 y on semaglutide; enobosarm 3/6 mg vs placebo.
Fundingindustry - Novo Nordisk (trial sponsor; inferred from registration trial)
Scope limitssmall sample (N~168)
Comparatorsplacebo + semaglutide